trial with title COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 – Canada

Who is eligible for the study?

The COMMANDS Trial may be an option for people who meet the following criteria:

• Be 18 years of age or older
• Have a diagnosis of MDS with anemia
• Require transfusions of blood cells

If you meet these initial criteria, we invite you to fill out the pre-screening questionnaire to find out if you are eligible to this study.

Confidentiality: Your privacy is important to us. The information you provide here will be used only by the study sponsor, its affiliated companies and its representatives to fulfill your request to learn more about the COMMANDS Trial, which is studying treatment for myelodysplastic syndromes (MDS), and to assess your eligibility for this trial. If you have any questions about the use of your information, please contact

Check if you are eligible Enter contact details Select a site

I consent to learn more about the COMMANDS Trial and I agree to share information about myself. I understand how this data will be used based on the above statements on this page.

Learn more about study participation

Study participation lasts approximately six years (and may be shorter or longer for some patients). This includes:
• A screening period of approximately 35 days,
• an initial treatment period of 24 weeks (which can be extended if certain criteria are met and if you continue to benefit from treatment), and
• a follow-up period where you will be contacted approximately every 12 weeks to ask how you are doing.

The study drug used in the COMMANDS Trial is a protein that aims to help increase the production of red blood cells in the bone marrow. The study drug will be administered by subcutaneous injection every three weeks during the treatment period.